Biofrontera AG

Back to All Transactions

Biofrontera AG
For more information regarding this transaction contact:
  • Dave McDonald Investment Banking 612.326.1268

Lake Street is pleased to announce it served as a joint bookrunner for Biofrontera AG (NasdaqCM:BFRA), an international biopharmaceutical company, in its underwritten public offering of 1,300,483 American Depositary Shares (ADSs), at an offering price of $9.88 per ADS. Each ADS represents two of Biofrontera’s ordinary shares, nominal value of €1.00 per share. The ADSs began trading on the NASDAQ Capital Markets under the symbol BFRA on February 14, 2018. Concurrently, Biofrontera completed a preemptive rights offering of its ordinary shares pursuant to German law to its existing holders of ordinary shares, under which Biofrontera will be issuing a total of 3,399,034 ordinary shares at an offering price of €4.00 per share (or approximately $4.94 per share, representing the same per share price as the one used in the ADS offering). These rights offering shares will trade on the Frankfurt Stock Exchange under the Company’s existing listing of B8F.F.

About Biofrontera AG

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera’s approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union.


Mike Townley
Head of Investment Banking


Email Mike

Dave McDonald
Head of Life Science Investment Banking


Email Dave


Tim Klein

Investment Banking


Email Tim


Rob Martin

Investment Banking


Email Rob


Steve Rickman

Investment Banking


Email Steve